Alamar Biosciences, Inc. filed a current report on Form 8-K on September 1, 2026, disclosing that its board of directors appointed Robert Ragusa as a Class I Director, effective September 1, 2026.

Key Highlights

  • New Director: Robert Ragusa was appointed to the Alamar Biosciences board of directors, effective September 1, 2026.
  • Board Class: Ragusa will serve as a Class I Director, with an initial term expiring at the Company's 2027 Annual Meeting of Stockholders.
  • Committee Assignments: Ragusa was appointed to the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee.
  • Compensation: Ragusa will be compensated under the Company's Non-Employee Director Compensation Policy, as described in the final prospectus filed with the SEC on April 17, 2026.
  • No Related Transactions: According to the filing, there are no related person transactions within the meaning of Item 404(a) of Regulation S-K between Ragusa and the Company required to be disclosed.

Robert Ragusa Joins Alamar Biosciences Board Across Three Committees

Alamar Biosciences, Inc. (NASDAQ:ALMR), headquartered at 47071 Bayside Parkway, Fremont, California, disclosed through an Item 5.02 filing that its board of directors voted on August 28, 2026, to appoint Robert Ragusa as a director. His appointment took effect September 1, 2026, the same day the filing was signed by Chief Financial Officer Justin McAnear.

According to the filing, Ragusa was simultaneously appointed to three board committees: the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee. As a Class I Director, his initial term is set to expire at the Company's 2027 Annual Meeting of Stockholders. The filing states that Ragusa will enter into the Company's standard form of indemnification agreement.

The filing further states that Ragusa's board compensation will follow the terms of the Company's Non-Employee Director Compensation Policy, "substantially as described in the Company's final prospectus filed with the U.S. Securities and Exchange Commission on April 17, 2026." The filing also states that "there were no arrangements or understandings between Mr. Ragusa and any other persons pursuant to which he was selected as a director," and that no related person transactions requiring disclosure exist between Ragusa and the Company under Item 404(a) of Regulation S-K.

What Was Disclosed

The filing reported the appointment of Robert Ragusa to the Alamar Biosciences board as a Class I Director, effective September 1, 2026, along with his assignment to three board committees and details of his compensation and indemnification arrangements.